Glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter 2 inhibitor use among adults with diabetes mellitus by cardiovascular-kidney disease risk: National Health and Nutrition Examination Surveys, 2015–2020

•GLP1-RAs and SGLT2Is lower the risk of adverse cardiac-kidney events in diabetes.•Only 10 % used GLP1-RAs or SGLT2Is, regardless of level of cardiac-kidney risk.•Few people who would benefit most from GLP1-RAs or SGLT2Is, were receiving them from 2015 to 2020.